Glioblastoma and the search for non-hypothesis driven combination therapeutics in academia
<p>Glioblastoma (GBM) remains a cancer of high unmet clinical need. Current standard of care for GBM, consisting of maximal surgical resection, followed by ionisation radiation (IR) plus concomitant and adjuvant temozolomide (TMZ), provides less than 15-month survival benefit. Efforts by conve...
Main Authors: | Johanssen, T, McVeigh, L, Erridge, S, Higgins, G, Straehla, J, Frame, M, Aittokallio, T, Carragher, NO, Ebner, D |
---|---|
Formato: | Journal article |
Publicado em: |
Frontiers Media
2023
|
Registos relacionados
-
A chemogenomic HTS for combinatorial drug discovery in glioblastoma
Por: Johanssen, T, et al.
Publicado em: (2022) -
Where are all the surgeons in clinical academia?
Por: McVeigh, J, et al.
Publicado em: (2022) -
Recent advances in the therapeutic strategies of glioblastoma multiforme
Por: Aldoghachi, Asraa Faris, et al.
Publicado em: (2022) -
Accelerating glioblastoma therapeutics via venture philanthropy
Por: Siah, Kien Wei, et al.
Publicado em: (2022) -
The violinist in London's concert life, 1750-1784 : Felice Giardini and his contemporaries
Por: McVeigh, S
Publicado em: (1979)